Collectively, these three studies have led to the proposals for some significant therapy regimens in GC patients: higher expression of JWA may be used as a biomarker for cisplatin treatment, lower expression of JWA may be utilized to identify patients that would benefit from HER2-targeted therapy; in terms of the anti-angiogenesis therapy, silencing of circRACGAP1 may be a potential intervention strategy to reduce the toxicities and promote the antitumor effect of apatinib. Here, ARL6IP5 is linked to gastric cancer.